Products

CHLOE BLAST
Fairtility
OB/GYN AI
CHLOE BLAST by Fairtility is an FDA-cleared, AI-powered cloud-based software that analyzes time-lapse embryo videos to provide objective decision support for embryo selection in IVF, aiming to improve success rates and standardize assessments.

See all 1 product →

About Fairtility

Fairtility is a pioneering healthcare AI company dedicated to revolutionizing In Vitro Fertilization (IVF) through advanced artificial intelligence and cloud-based diagnostic solutions. Their core offering, CHLOE™ (Cultivating Human Life through Optimal Embryos), is a transparent AI-based decision support tool designed to provide clinicians with unprecedented visibility into critical clinical and laboratory parameters throughout the IVF journey. This platform leverages sophisticated computer vision algorithms to analyze time-lapse embryo images, offering objective and consistent assessments of embryo and oocyte quality.

CHLOE™ aims to significantly improve IVF outcomes by predicting blastulation, implantation, and ploidy, and by ranking embryos for transfer, thereby reducing the inherent subjectivity in traditional embryo evaluation. The system supports embryologists and clinicians in making more informed decisions, streamlining workflows, and fostering clearer, more transparent communication with patients. Fairtility’s commitment to transparency ensures that medical professionals understand the biological data underpinning the AI’s recommendations, building trust and confidence in the technology.

Notably, Fairtility’s CHLOE Blast™ has achieved U.S. FDA 510(k) clearance, marking it as the first and only FDA-cleared machine learning AI-powered clinical decision support software for embryo assessment. The company is actively expanding CHLOE™’s application to encompass the entire reproductive care journey, from initial infertility cause assessment to optimizing embryo transfer, ultimately striving to enhance patient experience and increase the likelihood of successful live births.

Focus Areas

AI for IVF reproductive care embryo assessment oocyte assessment clinical decision support workflow optimization transparency in AI fertility treatments egg freezing family-building

Business Intelligence

Key InvestorsGurnet Point Capital, Nacre Capital, Kreos Capital, Innocreative Capital, Tal Ventures
PartnershipsvRepro, IDEAS from Mellowood Medical, nAble IVF, MedITEX (EMR integrations), Esco Medical (MIRI® Time-Lapse Incubators), various fertility clinics and academic institutions globally for clinical research
TechnologyCHLOE™ platform, transparent AI, cloud-based diagnosis solutions, computer vision algorithms, time-lapse imaging, machine learning, AI-powered clinical decision support software
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

AI for IVF & Reproductive Care
Fairtility specializes in applying transparent AI, primarily through its CHLOEu2122 platform, to enhance decision-making and outcomes across the entire In Vitro Fertilization (IVF) journey and broader reproductive care.
Embryo Assessment
Their flagship product, CHLOEu2122, offers AI-powered embryo assessment by continuously monitoring embryo development using time-lapse imaging, capturing images every 10 minutes. It analyzes minute features, assigns a viability score, and aids in selecting the optimal embryo for transfer, aiming to increase pregnancy success rates. CHLOE Blastu2122, an AI-powered embryo assessment tool, has received FDA 510(k) clearance.
Oocyte Assessment
Fairtility's CHLOE OQu2122 extends their AI capabilities to oocyte (egg) assessment, providing personalized data to support decision-making for egg freezing and egg donation. This tool helps assess egg quality and predicts an oocyte's potential to reach the blastocyst stage post-fertilization, assisting in patient counseling and treatment planning.
Clinical Decision Support
CHLOEu2122 serves as an AI-based decision support system, offering reproductive care practitioners objective, data-driven insights and analysis. It acts as a workflow enhancement tool, assisting fertility doctors and embryologists in making more informed and consistent decisions.
Workflow Optimization
By integrating with Electronic Medical Record (EMR) systems and time-lapse incubators, Fairtility's platform facilitates the digitalization of the embryology lab, enabling live, automatic data capture and processing. This streamlines clinical and operational workflows, leading to increased lab efficiency by up to 60% and reduced administrative time.
Transparency in AI & Fertility Treatments
A key differentiator is Fairtility's commitment to 'transparent AI', providing clinicians with complete visibility into the clinical and laboratory parameters used for assessment. They also enhance patient experience by offering real-time access to view embryo development through a mobile app, fostering greater understanding and engagement.
Key Differentiator: First FDA-Cleared AI for Embryo Assessment
Fairtility's CHLOE Blastu2122 is the first and only FDA-cleared machine learning AI-powered clinical decision support software for embryo assessment, setting a regulatory precedent in the field of reproductive medicine. This clearance allows them to offer their AI-powered technology in the U.S., building on successful implementations in Europe, Canada, and Asia Pacific.
Key Differentiator: Objective & Data-Driven Approach
Fairtility shifts embryo and oocyte assessment from subjective and manual evaluations to an objective, data-driven, and more automated process. Their AI algorithms are trained on vast datasets of embryo videos and clinical data, allowing for the analysis of minute features often undetectable by the human eye.
Technology Stack: AI/Machine Learning & Cloud
Their core technology relies on advanced AI and machine learning, including computer vision algorithms and convolutional neural networks, to interpret time-lapse imaging data. CHLOEu2122 is a cloud-based system, leveraging Google Cloud for robust data storage, analysis, development, and deployment, enabling scalability and real-time operations for clinics worldwide.
Physician Tip

For physicians, Fairtility's CHLOEu2122 platform offers a significant advancement in reproductive care by providing objective, data-driven insights for embryo and oocyte selection, thereby reducing subjectivity and improving consistency in assessments. This leads to enhanced clinical decision-making and potentially higher success rates for IVF treatments, while also reducing the number of cycles required for a live birth. The system's ability to streamline lab workflows, reduce administrative burden, and minimize manual note-taking can increase embryologist efficiency by up to 60%. Furthermore, the transparent AI approach and patient-facing tools, like the Embryo Development Vieweru2122, foster greater patient engagement and trust, allowing for clearer communication about treatment progress. CHLOE OQu2122 specifically aids in counseling patients on fertility preservation options like egg freezing and donation.

Fairtility's CHLOEu2122 platform is designed for seamless integration with existing clinic infrastructure. It successfully integrates with leading Electronic Medical Record (EMR) systems in the reproductive care market, including vRepro, IDEAS from Mellowood Medical, nAble IVF, and MedITEX. Additionally, CHLOEu2122 integrates with time-lapse incubators, such as Esco Medical's MIRIu00ae TL incubators, enabling automated annotation and analysis directly from the source. These integrations ensure a smooth flow of information, digitalizing the embryology lab and creating a unified data and insights hub for fertility clinics.

Products by Fairtility

1 product in the directory

CHLOE BLAST
Fairtility
OB/GYN AI
CHLOE BLAST by Fairtility is an FDA-cleared, AI-powered cloud-based software that analyzes time-lapse embryo videos to provide objective decision support for embryo selection in IVF, aiming to improve success rates and standardize assessments.

What the Web Says

Fairtility is a company that develops AI-powered decision support platforms for reproductive medicine, primarily known for its CHLOEu2122 system. This system aims to improve IVF outcomes by providing objective, AI-driven assessment and ranking of embryos and oocytes, and enhancing communication between clinicians and patients. The company has received FDA clearance for its CHLOE Blastu2122 tool and its technology has been commercially used in various regions outside the US.

Overall: Positive

Strengths

  • AI-based embryo selection outperforms manual assessment, potentially increasing IVF success rates and reducing multiple pregnancies.
  • Provides objective and consistent embryo evaluations, reducing subjectivity and variability among embryologists.
  • Offers transparent AI, making its reasoning visible by highlighting clinical markers that drive insights, which helps clinicians validate decisions and builds patient trust.
  • Integrates directly into time-lapse incubators, eliminating the need for data transfer and onsite technicians.
  • Can classify embryos as early as 30 hours post-fertilization, improving predictive ability over time.
  • Streamlines workflows, automates processes, and digitizes data management, leading to increased efficiency and accessibility for clinics.

Limitations

  • Some Reddit users express skepticism about whether AI tools significantly improve IVF success rates compared to traditional methods.
  • The CHLOE EQ system can be expensive, leading some prospective users to question its worth.
  • There can be discrepancies between AI scores and embryologist grades, causing confusion for patients.
  • Limited information is available on employer reviews on platforms like Glassdoor, G2, and Capterra specifically for Fairtility.
  • Some clinics consider the AI scoring system to be new and not yet routinely used for making definitive decisions.

Based on reviews from: BioWorld, Fairtility Website, Reddit, PR Newswire, BioPharma APAC, Harley Street Fertility Clinic

Last updated: 2026-07-18

Videos

News, demos, and interviews about Fairtility.

Loading videos...

Videos load interactively. If none appear, search YouTube for Fairtility →

View all on YouTube

Press & Coverage

Business Wire
Fairtility's CHLOEu2122 Platform Achieves FDA Clearance for AI-Powered Embryo Assessment Tool, CHLOE Blastu2122
Fairtility's CHLOE platform has received U.S. FDA 510(k) clearance for its AI-powered embryo assessment tool, CHLOE Blastu2122, making it the first and only FDA-cleared machine learning AI-powered clinical decision support software for embryo assessment. This clearance allows Fairtility to offer its AI-powered technology to clinics and patients in the U.S., where it has already been successfully implemented in Europe, Canada, and Asia Pacific.
2025-09
Femtech Insider
Fairtility Receives FDA Clearance for AI-Powered Embryo Assessment Tool
Fairtility has secured FDA 510(k) clearance for CHLOE Blast, an AI-powered embryo assessment tool within its CHLOE platform, which analyzes time-lapse embryo images for more objective evaluations. This regulatory milestone addresses rising infertility rates in the U.S. and sets a precedent for AI in reproductive medicine.
2025-09
Medtech Insight
Fairtility's FDA-Cleared CHLOE Brings AI To Embryo Selection
Fairtility's CHLOE platform, recently cleared by the FDA, utilizes AI to enhance the in vitro fertilization (IVF) process by providing more reliable, transparent, and efficient embryo assessment. This technology is now being introduced to clinics across the US to improve embryo selection.
2025-09
PR Newswire
Fairtility Integrates with Leading Electronic Medical Record Systems in the Reproductive Care Market, Advancing Digitalization of the IVF Clinic
Fairtility's AI decision support system, CHLOEu2122, has successfully integrated with major electronic medical record (EMR) platforms in fertility clinics, including vRepro, IDEAS, nAble IVF, and MedITEX. This integration aims to streamline data consolidation, standardize information, and enhance efficiency in reproductive care.
2023-10
Fairtility (via PR Newswire)
Fairtility Expands European Market Penetration with CHLOE EQu2122, as Clinics in Five Countries Embrace Breakthrough AI Technology in IVF
One year after receiving CE MDR clearance for CHLOE EQu2122, Fairtility has significantly expanded its presence across Europe, with clinics in the UK, Spain, Turkey, Greece, and Norway adopting its AI technology for IVF. CHLOE EQu2122 helps embryologists reduce manual annotation time by an average of 33% per cycle, increasing clinic availability.
2023-06
FemTech World
Fairtility closes US$15m series A funding round for advanced clinical research
Fairtility completed a US$15 million Series A funding round, led by Gurnet Point Capital, with participation from Nacre Capital and other investors. The funding will be used for advanced clinical research with fertility clinics and academic institutions globally, as well as for regulatory approvals and further development of the CHLOEu2122 platform.
2022-06
PR Newswire
Fairtility Granted CE Mark Under New European Medical Device Regulation (MDR) for AI Decision Support Tool, CHLOE EQu2122
Fairtility's AI decision support tool, CHLOE EQu2122, has received the CE Mark under the new European Medical Devices Regulation (MDR) requirements, making it commercially available to IVF fertility clinics across Europe. CHLOE EQu2122 provides embryo viability assessment, supporting predictions of blastulation, implantation, and ploidy, and ranks embryos.
2022-07
PR Newswire
Comprehensive Study Finds Fairtility's AI-Trained Embryo Labeling Improves Embryo Classification and Selection Success Rates for In Vitro Fertilization
A study published in Scientific Reports found that Fairtility's novel AI algorithms for embryo labeling outperformed human assessment and an existing FDA-approved system in predicting embryo potential. The AI algorithm provides accurate and transparent predictions as early as 30 hours post-fertilization, aiming to improve IVF success rates.
2022-04

Frequently Asked Questions

Fairtility's flagship AI platform, CHLOEu2122, is an AI-powered decision support system designed to optimize IVF outcomes by providing data-driven insights into embryo and oocyte viability. It aims to improve treatment success rates, reduce the number of IVF cycles needed for a live birth, and enhance the overall patient experience through increased transparency.
Fairtility offers specialized modules like CHLOE Blastu2122 for AI-powered embryo assessment, providing objective and consistent evaluations of time-lapse embryo images. Additionally, CHLOE OQu2122 delivers oocyte quality insights, supporting decision-making for fertility preservation, egg donation, and IVF applications.
Fairtility emphasizes 'transparent AI,' meaning its CHLOE platform provides not just scores or predictions, but also the underlying biological data and explanations for its assessments. This approach helps embryologists and clinicians understand the 'why' behind the AI's recommendations, fostering trust and enabling more informed, collaborative decision-making with patients.
CHLOE is designed to streamline operations by automating tasks like embryo annotation, which can reduce manual time by an average of 33% per cycle and increase lab efficiency by up to 60%. Its integration with leading Electronic Medical Record (EMR) systems further digitalizes the embryology lab, reducing administrative burdens and enhancing data flow for improved productivity.
Fairtility's CHLOE Blastu2122 has achieved U.S. FDA 510(k) clearance, making it the first and only FDA-cleared machine learning AI-powered clinical decision support software for embryo assessment. The CHLOE EQu2122 module also holds CE MDR clearance, demonstrating adherence to international medical device regulations.
While specific pricing models are not publicly detailed, Fairtility's use of cloud infrastructure suggests a scalable and potentially flexible approach. The company is committed to providing unparalleled support, including remote installation, deployment, and ongoing assistance for its international customer base.
Fairtility has formed strategic partnerships with leading IVF clinics globally and technology providers like Esco Medical, integrating CHLOE with MIRIu00ae Time-Lapse Incubators, and Google Cloud for its robust data infrastructure. The company secured $18.5 million in Series A funding in July 2025, indicating strong investor confidence and plans for continued global expansion and product development.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare fintech company that leverages AI and automation to address the growing challenge of healthcare affordability for patients and financial stability for providers. The platform offers personalized, interest-free payment plans, extending up to 60 months, tailored to each patient’s ability to pay. This approach aims to remove financial barriers to care, allowing […]

Healthcare Finance.AI is dedicated to optimizing healthcare revenue cycles through cutting-edge AI technologies. The company aims to improve financial outcomes for healthcare providers while supporting their commitment to quality care and efficiency. Their solutions are designed to enhance revenue cycle efficiency, reduce claim turnaround times, and improve patient billing accuracy. Their platform leverages advanced analytics […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School, a faculty of Imperial College London, is a leading institution that integrates business education with science, engineering, medicine, and technology. For physicians and healthcare providers, the Business School offers specialized programs and research focused on the intersection of AI, digital transformation, and healthcare management. Their curriculum is designed to equip healthcare […]

Columbia University, through its online learning platform edX, offers a range of educational programs, including those focused on artificial intelligence and its applications in healthcare. While not a direct AI product company, Columbia University provides foundational and advanced courses that equip physicians and healthcare providers with the knowledge and skills to understand, evaluate, and potentially […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.